JP2020507561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507561A5 JP2020507561A5 JP2019538396A JP2019538396A JP2020507561A5 JP 2020507561 A5 JP2020507561 A5 JP 2020507561A5 JP 2019538396 A JP2019538396 A JP 2019538396A JP 2019538396 A JP2019538396 A JP 2019538396A JP 2020507561 A5 JP2020507561 A5 JP 2020507561A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 239000012634 fragment Substances 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 101000741544 Homo sapiens Properdin Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 108010094020 polyglycine Proteins 0.000 claims 3
- 229920000232 polyglycine polymer Polymers 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022107980A JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2024095141A JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452187P | 2017-01-30 | 2017-01-30 | |
| US62/452,187 | 2017-01-30 | ||
| PCT/US2018/015985 WO2018140956A1 (en) | 2017-01-30 | 2018-01-30 | Monovalent anti-properdin antibodies and antibody fragments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107980A Division JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507561A JP2020507561A (ja) | 2020-03-12 |
| JP2020507561A5 true JP2020507561A5 (enExample) | 2021-03-04 |
| JP7101684B2 JP7101684B2 (ja) | 2022-07-15 |
Family
ID=62978808
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538396A Active JP7101684B2 (ja) | 2017-01-30 | 2018-01-30 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2022107980A Pending JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2024095141A Pending JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107980A Pending JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2024095141A Pending JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11198725B2 (enExample) |
| EP (1) | EP3573661A4 (enExample) |
| JP (3) | JP7101684B2 (enExample) |
| KR (2) | KR20230173731A (enExample) |
| CN (2) | CN118184777A (enExample) |
| AU (2) | AU2018212012B2 (enExample) |
| BR (1) | BR112019014652A2 (enExample) |
| CA (1) | CA3049806A1 (enExample) |
| CO (1) | CO2019007686A2 (enExample) |
| IL (2) | IL309890A (enExample) |
| MX (3) | MX2019008827A (enExample) |
| WO (1) | WO2018140956A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019028269A2 (pt) | 2017-07-11 | 2020-07-14 | Alexion Pharmaceuticals, Inc. | polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão |
| ES2974200T3 (es) * | 2018-09-13 | 2024-06-26 | Regeneron Pharma | Rata nuligénica para el gen del factor H del complemento como modelo de glomerulopatía C3 |
| WO2021140475A1 (en) * | 2020-01-08 | 2021-07-15 | Cadila Healthcare Limited | Anti-properdin antibodies and preparation thereof |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| WO2022089576A1 (zh) * | 2020-10-30 | 2022-05-05 | 广州市妇女儿童医疗中心 | 用于抑制mhc-i和/或ii信号通路的试剂在治疗胆道闭锁中的应用 |
| WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
| US11981727B2 (en) | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| CA3264087A1 (en) * | 2022-08-05 | 2024-02-08 | Alexion Pharma Inc | Pharmaceutical compositions based on fusion proteins and their methods of use |
| WO2024049951A1 (en) * | 2022-08-31 | 2024-03-07 | Alexion Pharmaceuticals, Inc. | Dosage and administration of fusion polypeptides for treatment of sickle cell disease |
| KR20250112858A (ko) | 2022-11-25 | 2025-07-24 | 리노 파마슈티컬스 아이엔씨. | 프로퍼딘 결합 단백질 및 이의 용도 |
| CN120399074A (zh) * | 2023-06-02 | 2025-08-01 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| JP5735194B2 (ja) | 2005-01-25 | 2015-06-17 | セル セラピューティクス インコーポレーテッド | 改善された生体内半減期を有する生物学的に活性なタンパク質 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ES2551202T5 (es) * | 2005-11-04 | 2018-11-30 | Genentech, Inc. | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| WO2011112850A2 (en) * | 2010-03-10 | 2011-09-15 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| ES2538114T3 (es) * | 2008-03-03 | 2015-06-17 | Novelmed Therapeutics, Inc. | Anticuerpos anti-properdina |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| EA024507B1 (ru) * | 2010-09-28 | 2016-09-30 | Амилин Фармасьютикалс, Ллк | Хорошо растворимые лептины |
| KR101650995B1 (ko) * | 2010-11-08 | 2016-08-25 | 노파르티스 아게 | Ｃｘｃｒ２ 결합 폴리펩티드 |
| WO2013006449A2 (en) * | 2011-07-01 | 2013-01-10 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| CN104271588B (zh) * | 2011-07-08 | 2017-10-10 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| CA2862448A1 (en) * | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| AU2013326932B2 (en) | 2012-10-04 | 2019-06-06 | Novelmed Therapeutics, Inc. | Alternative pathway specific antibodies for treating hemolytic diseases |
| NL2013661B1 (en) * | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN110003335B (zh) * | 2019-04-12 | 2023-07-04 | 深圳普瑞金生物药业股份有限公司 | Cd47单域抗体、核酸及试剂盒 |
-
2018
- 2018-01-30 KR KR1020237042534A patent/KR20230173731A/ko not_active Ceased
- 2018-01-30 CA CA3049806A patent/CA3049806A1/en active Pending
- 2018-01-30 KR KR1020197021910A patent/KR102613874B1/ko active Active
- 2018-01-30 IL IL309890A patent/IL309890A/en unknown
- 2018-01-30 CN CN202410325026.7A patent/CN118184777A/zh active Pending
- 2018-01-30 CN CN201880008892.6A patent/CN110831626B/zh active Active
- 2018-01-30 WO PCT/US2018/015985 patent/WO2018140956A1/en not_active Ceased
- 2018-01-30 BR BR112019014652-0A patent/BR112019014652A2/pt unknown
- 2018-01-30 IL IL267898A patent/IL267898B2/en unknown
- 2018-01-30 MX MX2019008827A patent/MX2019008827A/es unknown
- 2018-01-30 JP JP2019538396A patent/JP7101684B2/ja active Active
- 2018-01-30 EP EP18744926.9A patent/EP3573661A4/en active Pending
- 2018-01-30 US US16/479,335 patent/US11198725B2/en active Active
- 2018-01-30 AU AU2018212012A patent/AU2018212012B2/en active Active
-
2019
- 2019-07-17 CO CONC2019/0007686A patent/CO2019007686A2/es unknown
- 2019-07-25 MX MX2023004333A patent/MX2023004333A/es unknown
- 2019-07-25 MX MX2023007840A patent/MX2023007840A/es unknown
-
2022
- 2022-07-04 JP JP2022107980A patent/JP2022153405A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095141A patent/JP2024116321A/ja active Pending
-
2025
- 2025-02-03 AU AU2025200709A patent/AU2025200709A1/en active Pending